Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development

LAKE FOREST, Calif., Sept. 18 Worldwide markets ofapproved EGFr/HEr2 inhibitors grew by 34.2% during the first half of 2007,pushing sales to more than $3.2 billion, exceeding total sales reported in2005. Hundreds of clinical trials are ongoing, aimed at expanding indicationsfor these drugs and fueling continued rapid market growth. In addition to theseven marketed ErbB-pathway inhibitors, more than 50 novel agents targetingthis pathway are in development.

"The ErbB Pathway in Cancer" is a series of comprehensive reportspublished in Future Oncology, New Medicine's premiere newsletter. FutureOncology provides analysis of critical issues in global cancer R&D, clinicalpractices, markets, and business and company developments. The series coversevery aspect of the EGFr/HEr2 inhibitor marketplace, including:

This series, published in 5 parts, is available for purchase in electronicPDF or hard copy format.-- Markets (USA and ROW) of approved drugs and forecasts -- Treatment costs in the USA and ROW -- Detailed ErbB pathway analyses -- Associations of ErbB expression and mutations with specific indications -- EGFr/HEr2-based diagnostic/theragnostic technologies and products -- Detailed profiles of currently approved drugs -- Comprehensive reviews of current use of approved drugs by indication -- Comprehensive reviews of new indications of approved drugs -- Protocols and interim and final results from clinical trials combining approved ErbB pathway inhibitors with novel agents. -- Detailed profiles of over 50 agents in development targeting the ErbB pathway, including protocols and interim and final results from hundreds of trials

SOURCE New Medicine

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...